ATE64416T1 - Die verwendung des gal 1 hefe-promotors. - Google Patents

Die verwendung des gal 1 hefe-promotors.

Info

Publication number
ATE64416T1
ATE64416T1 AT84101937T AT84101937T ATE64416T1 AT E64416 T1 ATE64416 T1 AT E64416T1 AT 84101937 T AT84101937 T AT 84101937T AT 84101937 T AT84101937 T AT 84101937T AT E64416 T1 ATE64416 T1 AT E64416T1
Authority
AT
Austria
Prior art keywords
gene
gal
segment
dna
vector
Prior art date
Application number
AT84101937T
Other languages
English (en)
Inventor
David Botstein
Ronald Wayne Davis
Gerald Ralph Fink
Alison Taunton-Rigby
Robert Gentry Knowlton
Jen-I Mao
Donald Taylor Moir
Christopher Godfrey Goff
Original Assignee
Collaborative Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23869556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE64416(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Collaborative Res Inc filed Critical Collaborative Res Inc
Application granted granted Critical
Publication of ATE64416T1 publication Critical patent/ATE64416T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478Aspartic endopeptidases (3.4.23)
    • C12N9/6481Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/911Microorganisms using fungi
    • Y10S435/94Saccharomyces
    • Y10S435/942Saccharomyces cerevisiae
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/12Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/14Lymphokine; related peptides
    • Y10S930/142Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Road Signs Or Road Markings (AREA)
  • Vessels, Lead-In Wires, Accessory Apparatuses For Cathode-Ray Tubes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Devices For Indicating Variable Information By Combining Individual Elements (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Prostheses (AREA)
AT84101937T 1983-02-28 1984-02-23 Die verwendung des gal 1 hefe-promotors. ATE64416T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/470,911 US4661454A (en) 1983-02-28 1983-02-28 GAL1 yeast promoter linked to non galactokinase gene
EP84101937A EP0123811B1 (de) 1983-02-28 1984-02-23 Die Verwendung des GAL 1 Hefe-Promotors

Publications (1)

Publication Number Publication Date
ATE64416T1 true ATE64416T1 (de) 1991-06-15

Family

ID=23869556

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84101937T ATE64416T1 (de) 1983-02-28 1984-02-23 Die verwendung des gal 1 hefe-promotors.

Country Status (8)

Country Link
US (1) US4661454A (de)
EP (1) EP0123811B1 (de)
JP (1) JPS6058077A (de)
AT (1) ATE64416T1 (de)
CA (1) CA1283373C (de)
DE (1) DE3484689D1 (de)
DK (1) DK97784A (de)
GB (1) GB2137208B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0128743A3 (de) * 1983-06-07 1985-12-27 Genex Corporation Expression von Fremdgenen in Hefe
EP0132309A3 (de) * 1983-06-27 1985-12-27 The Board Of Trustees Of The Leland Stanford Junior University Regulierbares eukaryotisches Promotorelement
IL71555A (en) * 1984-04-15 1992-06-21 State Of Israel Israel Inst Fo Bovine interferon
US4990446A (en) * 1984-12-06 1991-02-05 Labofina, S.A. Promoters for the expression of foreign genes in yeast, plasmids comprising them, and use thereof for the production of polypeptides
US5037806A (en) * 1985-02-22 1991-08-06 Monsanto Company Biologically active method using somatotropins
US4861868A (en) 1985-02-22 1989-08-29 Monsanto Company Production of proteins in procaryotes
EP0225887B1 (de) * 1985-04-08 1994-06-08 Amgen Inc. Verfahren und hybridpromotor zur steuerung der exogenen gentranskription
JP2677350B2 (ja) * 1985-08-02 1997-11-17 メルク エンド カムパニ− インコ−ポレ−テツド 発現蛋白の発酵収率増大
JPH0668B2 (ja) * 1985-08-30 1994-01-05 財団法人化学及血清療法研究所 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
US5002876A (en) * 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US5013652A (en) * 1986-10-14 1991-05-07 Genex Corporation Composite yeast vectors
US5882884A (en) * 1987-06-19 1999-03-16 Lucky Biotech Corporation Expression of proteinaceous sweeteners in yeast
US5487990A (en) * 1988-07-01 1996-01-30 The General Hospital Corporation Glucose-regulated promoter of yeast acetyl-CoA hydrolase
US5057419A (en) * 1988-09-22 1991-10-15 Rutgers University Genetically engineered plasmid and organisms for the production of specialized oils
US5187079A (en) * 1988-12-21 1993-02-16 The Research Foundation Of State University Of New York Glucose-repressible gene for the regulated expression of proteins and expression vector therefor
WO1991014780A1 (en) * 1990-03-21 1991-10-03 Board Of Regents, The University Of Texas System Yeast expression vectors
AU652576B2 (en) 1990-09-13 1994-09-01 Duke University Expression of G protein coupled receptors in yeast
JPH04287683A (ja) * 1991-03-14 1992-10-13 Ajinomoto Co Inc 酵母変異株およびそれを利用するペプチドまたは蛋白質           等の製造方法
GB9226065D0 (en) * 1992-12-14 1993-02-10 Ici Plc Peptides
DE4303744A1 (de) * 1993-02-09 1994-08-11 Univ Autonoma De Nuevo Leon Mo Hundewachstumshormon
DE19534120A1 (de) 1995-09-14 1997-03-20 Hoechst Ag Verwendung von Cytohesin-PH-Peptiden zur Beeinflußung der Adhäsionsfähigkeit von Integrinen
AU1206397A (en) 1995-12-29 1997-07-28 Guilford Pharmaceuticals Inc. Method and kit for detection of multiple protein interactions
US5886151A (en) * 1996-05-03 1999-03-23 Regents Of The University Of Minnesota Candida albicans integrin-like protein
WO1998016644A1 (en) 1996-10-16 1998-04-23 Zymogenetics, Inc. Fibroblast growth factor homologs
US6265186B1 (en) 1997-04-11 2001-07-24 Dsm N.V. Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
GB9726897D0 (en) * 1997-12-20 1998-02-18 Zeneca Ltd Process
JP4704565B2 (ja) 1998-09-23 2011-06-15 ザイモジェネティクス, インコーポレイテッド サイトカインレセプターzalpha11
ATE404668T1 (de) 1998-12-07 2008-08-15 Zymogenetics Inc Wachstumsfaktor-homologe zvegf-3
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
ATE437227T1 (de) 1999-01-07 2009-08-15 Zymogenetics Inc Verfahren zur therapeutischen verwendung von löslichen rezeptoren br43x2
EP1881070B1 (de) 1999-03-09 2012-10-03 Zymogenetics, Inc. Menschliche Zytokine als Liganden des Z-Alpha-Rezeptors und Verwendungen davon
ES2364086T3 (es) 1999-07-07 2011-08-24 Zymogenetics, Inc. Receptor de citoquina humana.
EP2194130A1 (de) 1999-12-23 2010-06-09 ZymoGenetics, L.L.C. Zytokin ZCYT018
EP1278852B1 (de) 2000-05-11 2010-07-07 ZymoGenetics, Inc. Zsig33-ähnliche peptide
AU2001273032A1 (en) 2000-06-26 2002-01-08 Zymogenetics Inc. Cytokine receptor zcytor17
ATE404670T1 (de) 2000-06-30 2008-08-15 Zymogenetics Inc Allelische variante des interferon-ähnlichen proteins zcyto21
EP1736545A3 (de) 2000-08-08 2007-03-28 ZymoGenetics, Inc. Lösliche Zcyctor 11 Cytokinrezeptoren
WO2002053747A1 (en) * 2000-12-28 2002-07-11 Toyota Jidosha Kabushiki Kaisha Process for producing prenyl alcohol
EP2301971A1 (de) 2001-02-20 2011-03-30 ZymoGenetics, L.L.C. Antikörper, die sowohl BCMA als auch TACI binden
PT1436003E (pt) 2001-05-24 2010-03-12 Zymogenetics Inc Proteínas de fusão imunoglobulina taci
AU2002336676A1 (en) 2001-11-05 2003-05-19 Zymogenetics, Inc Il-21 antagonists
PL211833B1 (pl) 2002-01-18 2012-06-29 Zymogenetics Inc Wyizolowany polipeptyd, białko fuzyjne, wyizolowana cząsteczka polinukleotydu, wektor ekspresji, hodowana komórka, sposób wytwarzania polipeptydu, sposób wytwarzania przeciwciała, przeciwciało, przeciwciało lub fragment przeciwciała, zastosowanie przeciwciała, sposób wykrywania obecności polipeptydu, sposób inhibicji proliferacji lub różnicowania komórek krwiotwórczych, zastosowanie polipeptydu, sposób rozprzestrzeniania komórek krwiotwórczych, sposób wykrywania obecności RNA, sposób zabijania komórek nowotworowych in vitro lub in vivo, zastosowanie polipeptydu, zastosowanie antagonisty polipeptydu i sposób wykrywania zapalenia u pacjenta
PT1576112E (pt) 2002-01-18 2012-05-25 Zymogenetics Inc Multímeros de receptor de citocina zcytor17
BR0309401A (pt) 2002-04-19 2007-02-21 Zymogenetics Inc polinucleotìdeo isolado, vetor de expressão, célula cultivada, método para produzir polipeptìdeos, e um anticorpo para um polipeptìdeo, e, anticorpo
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US7785871B2 (en) * 2002-10-09 2010-08-31 Intrexon Corporation DNA cloning vector plasmids and methods for their use
US20080050808A1 (en) * 2002-10-09 2008-02-28 Reed Thomas D DNA modular cloning vector plasmids and methods for their use
ES2303132T3 (es) 2003-08-07 2008-08-01 Zymogenetics, Inc. Preparaciones homogeneas de il-29.
CN1283792C (zh) * 2003-11-14 2006-11-08 余伟明 生物大分子组分相分离法
WO2005087810A2 (en) 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
ES2603062T3 (es) * 2004-05-18 2017-02-23 Intrexon Corporation Métodos de ensamblaje dinámico de vectores para la clonación de ADN de vectores plasmídicos
CN101829318B (zh) 2004-07-29 2012-07-04 津莫吉尼蒂克斯有限责任公司 Il-28和il-29治疗癌症和自身免疫性疾病的用途
EP2166103B1 (de) 2004-08-02 2013-05-22 BASF Plant Science GmbH Verfahren zur Isolierung von Transkriptionsabschlusssequenzen
CA2596390A1 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
ATE515512T1 (de) 2005-05-12 2011-07-15 Zymogenetics Inc Zusammensetzungen und verfahren zur modulierung von immunreaktionen
AU2006278227B2 (en) 2005-08-09 2011-10-20 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
WO2007019575A2 (en) * 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
US8153598B2 (en) * 2005-10-19 2012-04-10 Intrexon Corporation PKD ligands and polynucleotides encoding PKD ligands
AU2007249223B2 (en) * 2006-05-15 2012-08-02 Ares Trading S.A. Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
US20100240597A1 (en) 2007-06-15 2010-09-23 Arkansas State University Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
AU2008298603B2 (en) 2007-09-14 2015-04-30 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN103059118B (zh) 2007-11-21 2017-11-24 罗斯基勒大学 具有冰结合活性的多肽
WO2009080054A1 (en) * 2007-12-21 2009-07-02 Ifxa A/S Protease inhibitor
BRPI0907640A2 (pt) * 2008-01-25 2015-11-03 Univ Aarhus inibição exosítio-seletiva da atividade de papp-a contra igfbp-4
EP2604279A1 (de) 2008-03-27 2013-06-19 ZymoGenetics, Inc. Zusammensetzungen und Verfahren zur Hemmung von PDGFR-beta und VEGF-A
EP2313105B1 (de) 2008-06-27 2013-07-24 ZymoGenetics, Inc. LÖSLICHE HYBRID-Fc gamma-REZEPTOREN UND ENTSPRECHENDE VERFAHREN
BR112012031329A2 (pt) 2010-06-09 2016-10-11 Zymogenetics Inc proteínas de fusão diméricas vstm3 e composições e métodos relacionados
EP3597764A3 (de) 2012-02-01 2020-05-06 SGI-DNA, Inc. Material und verfahren zur synthese von fehlerminimierten nukleinsäuremolekülen
WO2014202089A2 (en) 2013-06-18 2014-12-24 Roskilde Universitet Variants of anti-freeze polypeptides
CN106318942B (zh) * 2015-06-29 2018-12-25 中国科学院大连化学物理研究所 一种半乳糖激酶启动子和终止子及其应用
CN106318943B (zh) * 2015-06-29 2019-03-05 中国科学院大连化学物理研究所 半乳糖激酶启动子和终止子及其应用
DK3328881T3 (da) 2015-09-08 2019-10-07 Theripion Inc Apoa-1 fusionspolypeptider og relaterede sammensætninger og fremgangsmåder
WO2018136163A2 (en) 2016-12-09 2018-07-26 Theripion, Inc. Tandem apoa-1 fusion polypeptides
KR102649757B1 (ko) 2017-07-20 2024-03-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 5t4 및 4-1bb에 결합하는 항원 결합 단백질 및 관련 조성물 및 방법
CA3085861C (en) 2017-12-20 2023-09-26 Harbour Biomed (Shanghai) Co., Ltd Antibodies binding ctla-4 and uses thereof
WO2019132765A1 (en) 2017-12-27 2019-07-04 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
US10150801B1 (en) 2017-12-27 2018-12-11 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
US10675332B1 (en) 2019-08-26 2020-06-09 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
WO2021040610A1 (en) 2019-08-26 2021-03-04 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
JP2023538476A (ja) 2020-06-22 2023-09-08 イミュナミ ラボラトリーズ プライベート リミティド 癌治療における使用のための組換えポリペプチド及び組合せ
AU2022224584A1 (en) 2021-02-19 2023-09-21 Theripion, Inc. Paraoxonase fusion polypeptides and related compositions and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443539A (en) * 1980-02-05 1984-04-17 The Upjohn Company Process for preparing bovine growth hormone
US4666847A (en) * 1981-01-16 1987-05-19 Collaborative Research, Inc. Recombinant DNA means and method
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
EP0128743A3 (de) * 1983-06-07 1985-12-27 Genex Corporation Expression von Fremdgenen in Hefe
EP0132309A3 (de) * 1983-06-27 1985-12-27 The Board Of Trustees Of The Leland Stanford Junior University Regulierbares eukaryotisches Promotorelement

Also Published As

Publication number Publication date
CA1283373C (en) 1991-04-23
DK97784A (da) 1984-08-29
US4661454A (en) 1987-04-28
JPS6058077A (ja) 1985-04-04
EP0123811A3 (en) 1986-03-26
GB8405129D0 (en) 1984-04-04
EP0123811A2 (de) 1984-11-07
DK97784D0 (da) 1984-02-24
EP0123811B1 (de) 1991-06-12
GB2137208A (en) 1984-10-03
GB2137208B (en) 1987-05-13
DE3484689D1 (de) 1991-07-18

Similar Documents

Publication Publication Date Title
ATE64416T1 (de) Die verwendung des gal 1 hefe-promotors.
ATE111156T1 (de) Transientes expressionssystem zur herstellung von rekombinantem protein.
ES8602138A1 (es) Metodo de controlar la expresion de un gen que codifica una proteinaheterologa deseada.
SE8007998L (sv) Forfarande for framstellning av interferon
KR920012442A (ko) 피치아 파스토리스 산성 인산효소 유전자의 dna 단편 및 이를 사용하는 방법
DE3888561T2 (de) Hohe Proteinsyntheserate in Hefe.
DK0378382T3 (da) Rekombinant DNA-fremgangsmåde og værtsceller
DK102886D0 (da) Proteinfaktorer
DE69331908D1 (de) Verfahren zur erhöhung der expression und zur verminderung der expressionsvariabilität von fremdgenen in pflanzenzellen
Huttner et al. DNA-mediated gene transfer without carrier DNA.
ATE67242T1 (de) Verfahren zur verbesserung der expression von eukaryontenprotein.
ES2013353A6 (es) Metodo de adn recombonante para producir proteinas fijadoras de oxigeno, particularmente hemoglobinas.
DK0749489T3 (da) Ekspressionskassette, der omfatter en promotor stammende fra pho4-genet fra Schizosaccharomyces pombe
DE69023101D1 (de) Bakterielles Kollagenase-Gen.
ATE90386T1 (de) Verfahren zur expression von genen in hefe, dns- fragmente und plasmide die letztere fragmente enthalten und zur durchfuehrung des verfahrens verwendet werden.
DE58909205D1 (de) Expressionsvektor und Verfahren zur regulierbaren Herstellung von Proteinen in Eukaryonten.
ATE107358T1 (de) System der induzierbaren positiven regulation zur verwendung für die herstellung von heterologen proteinen.
ATE85358T1 (de) Verfahren zur herstellung von plasminogenaktivatoren in prokaryonten.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties